JP4164538B2 - 内臓脂肪蓄積抑制剤 - Google Patents
内臓脂肪蓄積抑制剤 Download PDFInfo
- Publication number
- JP4164538B2 JP4164538B2 JP2007539844A JP2007539844A JP4164538B2 JP 4164538 B2 JP4164538 B2 JP 4164538B2 JP 2007539844 A JP2007539844 A JP 2007539844A JP 2007539844 A JP2007539844 A JP 2007539844A JP 4164538 B2 JP4164538 B2 JP 4164538B2
- Authority
- JP
- Japan
- Prior art keywords
- visceral fat
- compound
- present
- fat accumulation
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001596 intra-abdominal fat Anatomy 0.000 title claims description 104
- 238000009825 accumulation Methods 0.000 title claims description 78
- 239000003112 inhibitor Substances 0.000 title claims description 34
- 150000001875 compounds Chemical class 0.000 claims description 89
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 35
- 239000000284 extract Substances 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 31
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 26
- 239000004480 active ingredient Substances 0.000 claims description 22
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 18
- 241000234280 Liliaceae Species 0.000 claims description 12
- IYIFZADLIMVECH-QYQNSBOUSA-N (9r,10s,13r,14r,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-4,10,13-trimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound CC1C(O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CCC21 IYIFZADLIMVECH-QYQNSBOUSA-N 0.000 claims description 9
- AOQRDALGACAKHI-KVCRWQBISA-N (9r,10s,13r,14r,17r)-17-[(2r,5s)-5,6-dimethylheptan-2-yl]-4,10,13-trimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound CC1C(O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@H](C)C(C)C)CC[C@H]33)C)C3=CCC21 AOQRDALGACAKHI-KVCRWQBISA-N 0.000 claims description 9
- AOQRDALGACAKHI-UHFFFAOYSA-N 4-methylergost-7-en-3-ol Natural products CC1C(O)CCC2(C)C(CCC3(C(C(C)CCC(C)C(C)C)CCC33)C)C3=CCC21 AOQRDALGACAKHI-UHFFFAOYSA-N 0.000 claims description 9
- IYIFZADLIMVECH-UHFFFAOYSA-N 4-methylstigmast-7-en-3-ol Natural products CC1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CCC21 IYIFZADLIMVECH-UHFFFAOYSA-N 0.000 claims description 9
- LMYZQUNLYGJIHI-SPONXPENSA-N 4alpha-methyl-5alpha-cholest-7-en-3beta-ol Chemical compound C[C@@H]1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 LMYZQUNLYGJIHI-SPONXPENSA-N 0.000 claims description 9
- LMYZQUNLYGJIHI-UHFFFAOYSA-N Methostenol Natural products CC1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CCC21 LMYZQUNLYGJIHI-UHFFFAOYSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002021 butanolic extract Substances 0.000 claims 1
- 239000002024 ethyl acetate extract Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 description 40
- 208000008589 Obesity Diseases 0.000 description 35
- 235000020824 obesity Nutrition 0.000 description 35
- 238000012360 testing method Methods 0.000 description 35
- 230000000694 effects Effects 0.000 description 24
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 239000003814 drug Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 241000196324 Embryophyta Species 0.000 description 15
- 235000011399 aloe vera Nutrition 0.000 description 15
- 208000001145 Metabolic Syndrome Diseases 0.000 description 14
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 14
- 230000037396 body weight Effects 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 230000036541 health Effects 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- 235000002961 Aloe barbadensis Nutrition 0.000 description 9
- 244000186892 Aloe vera Species 0.000 description 9
- 210000000577 adipose tissue Anatomy 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 235000019786 weight gain Nutrition 0.000 description 9
- -1 cholestenone compound Chemical class 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000037356 lipid metabolism Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 230000004584 weight gain Effects 0.000 description 7
- 241001116389 Aloe Species 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 125000000547 substituted alkyl group Chemical group 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 210000001624 hip Anatomy 0.000 description 4
- 235000002378 plant sterols Nutrition 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000013293 zucker diabetic fatty rat Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- NYOXRYYXRWJDKP-UHFFFAOYSA-N cholestenone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 NYOXRYYXRWJDKP-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000020805 dietary restrictions Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 210000003918 fraction a Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 210000004003 subcutaneous fat Anatomy 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 240000007474 Aloe arborescens Species 0.000 description 2
- 235000004509 Aloe arborescens Nutrition 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- 244000101643 Aloe ferox Species 0.000 description 2
- 235000015858 Aloe ferox Nutrition 0.000 description 2
- 241000782139 Aloe spicata Species 0.000 description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 229940069521 aloe extract Drugs 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 2
- 235000000431 campesterol Nutrition 0.000 description 2
- NYOXRYYXRWJDKP-GYKMGIIDSA-N cholest-4-en-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 NYOXRYYXRWJDKP-GYKMGIIDSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000002196 fr. b Anatomy 0.000 description 2
- 210000000540 fraction c Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000002475 laxative effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000009925 nephrosclerosis Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- ATIPVUGMJZAJPC-SRGSQMPJSA-N (8s,9s,10r,13r,14s,17r)-17-[(2r)-5,6-dimethylheptan-2-yl]-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCC(C)C(C)C)[C@@]1(C)CC2 ATIPVUGMJZAJPC-SRGSQMPJSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 241001073152 Aloe africana Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012665 Diabetic gangrene Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- GGCLNOIGPMGLDB-GYKMGIIDSA-N cholest-5-en-3-one Chemical class C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GGCLNOIGPMGLDB-GYKMGIIDSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000021130 excess caloric intake Nutrition 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000002957 persistent organic pollutant Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Steroid Compounds (AREA)
Description
脂肪型肥満と、内臓脂肪が蓄積する内臓脂肪型肥満が知られているが、特に内臓脂肪の蓄積が、肥満における代謝異常・循環器疾患等の合併症発症頻度や重症度に強い影響を及ぼす。
1)前記化合物中のR2及びR3の一方が水素原子であり、他方がメチル基であり、R4が水酸基であること、
からなる群から選ばれること、
5)前記化合物中のR2及びR3の一方が水素原子であり、他方がメチル基であり、R4が水酸基であること、
また、以下の8)を好ましい態様としている。
8)飲食品が、前記一般式(1)で示される化合物を0.0001質量%以上含むこと。
本発明の上記使用及び方法における前記一般式(1)で表される化合物の好ましい態様は、本願第二の発明と同様である。
いる化合物は、前記一般式(1)で表される構造をもつ化合物であって、内臓脂肪蓄積抑制作用を有する化合物(以下、「本発明の化合物」ともいう)であれば、いずれの誘導体等も有効成分として含まれる。
))、及び4−メチルスチグマスト−7−エン−3−オール(式(4))である。
メチルエルゴスト−7−エン−3−オールは、前記一般式(1)において、R2及びR3の一方が水素原子であり、他方がメチル基であり、R4が水酸基であって、R1が前記式(vi)で表される基(但し、Rc及びRdはともに−CH3である)。また、4−メチルスチグマスト−7−エン−3−オールは、前記一般式(1)において、R2及びR3の一方が水素原子であり、他方がメチル基であり、R4が水酸基であって、R1が前記式(i)で表される基である。
リカゲルカラムクロマトグラフィーにおいては、溶出溶媒としてヘキサン/酢酸エチル混合液(4:1)を用いると、本発明の化合物は最初の方のフラクションとして溶出される。得られたフラクションは、さらにHPLC等により精製することができる。
0mg/kg/日、好ましくは、1〜100mg/kg/日となるような量を目安とするのが良い。いずれの場合も、1日1回又は複数回に分けて投与することができる。
需要者が上記用途を直接的に認識できるような表現により表示することが好ましい。具体的には、本発明の飲食品に係る商品又は商品の包装に上記用途を記載する行為、商品又は商品の包装に上記用途を記載したものを譲渡し、引渡し、譲渡若しくは引渡しのために展示し、輸入する行為、商品に関する広告、価格表若しくは取引書類に上記用途を記載して展示し、若しくは頒布し、又はこれらを内容とする情報に上記用途を記載して電磁気的(インターネット等)方法により提供する行為、等が例示できる。一方、表示としては、行政等によって認可された表示(例えば、行政が定める各種制度に基づいて認可を受け、そのような認可に基づいた態様で行う表示)であることが好ましく、特に包装、容器、カタログ、パンフレット、POP等の販売現場における宣伝材、その他の書類等への表示が好ましい。
[製造例1]
アロエベラの葉肉(透明ゲル部分)100kgを、ホモジナイザーを用いて液状化し、ここに100Lの酢酸エチル/ブタノール混合液(3:1)を添加して攪拌した。一晩放置した後、酢酸エチル/ブタノール混合液と水層を分液して、酢酸エチル/ブタノール混合液を回収した。この酢酸エチル/ブタノール混合液を減圧下濃縮して得られた、酢酸エチル/ブタノール混合液抽出物の重量は、13.5gであった。シリカゲル60(メルク社製)を400g充填しカラムに、当該抽出物13gを1mlのクロロホルム/メタノール混合液(1:1)に溶解させた溶液を流してカラムに吸着させた後、クロロホルム/メタノール混合液(クロロホルム:メタノール=100:1、25:1、10:1、5:1及び1:1の各混合比)を使用し、メタノール濃度を段階的に上昇させるステップワイズグラジエント法により溶出し、前記混合液の混合比毎に溶出液を分画した。これらのフラクションのうち、クロロホルム:メタノール=25:1で溶出してきたフラクションに本発明の化合物が存在することを、順相及び逆相薄層クロマトグラフィー(メルク社製、シリカゲル60F254及びRP−18F2543)にて確認した。
及び逆相薄層クロマトグラフィーにて確認した。この粗精製物2を、さらに、コスモシールC18(ナカライテスク社製)を装着したHPLCを用いて、クロロホルム/ヘキサン混合液(85:15)にて分離し、化合物3(4−メチルコレスト−7−エン−3−オール)、化合物4(4−メチルエルゴスト−7−エン−3−オール)、化合物5(4−メチルスチグマスト−7−エン−3−オール)を、それぞれ1.3mg、1.2mg、1mg得た。各々の化合物の構造はMSおよびNMRにて確認した。
前記製造例1で製造した化合物3(4−メチルコレスト−7−エン−3−オール)、化合物4(4−メチルエルゴスト−7−エン−3−オール)、化合物5(4−メチルスチグマスト−7−エン−3−オール)を、それぞれ試験試料1、試験試料2、試験試料3とした。各試料をDMSOに溶解した後、蒸留水にて、各試験試料における化合物の濃度が10μg/mlとなるように試験試料1−1、試験試料2−1、及び試験試料3−1として調製した。また、1μg/mlになるように試験試料1−2、試験試料2−2、及び試験試料3−2として調製した。なお、DMSOの最終濃度は0.2%になるように調整した。さらに、試料を含まない溶液を陰性試料とした。
6週齢、雄性ZDFラット(米国チャールスリバー社より購入)を、高脂肪食(リサーチダイエット社製)を用いて1ヶ月間予備飼育を行った後、1群6匹に群分けした。各群のラットに、1日1回ゾンデを用いて、陰性試料、試験試料1−1、試験試料1−2、試験試料2−1、試験試料2−2、試験試料3−1、及び試験試料3−2の各溶液をそれぞれラット体重400gにつき1mlずつ44日間連日経口投与した。投与開始から45日目に内臓脂肪として腸管膜脂肪重量を測定した。
投与開始から45日目の腸管膜脂肪重量を表1に示す。陰性試料投与群のラット腸管膜脂肪重量(6.83±1.10g)に比べ、化合物の濃度が10μg/mlである試験試料1−1、試験試料2−1、及び試験試料3−1では、それぞれ脂肪量が、4.48±1.34g、3.78±0.26g、及び3.36±1.67gとなり、それぞれ陰性試料群の65.0%、54.9%および48.7%の脂肪量を示して、内臓脂肪の有意な蓄積抑制効果が確認された。一方、化合物の濃度が1μg/mlである試験試料1−2、試験試料2−2、及び試験試料3−2では、いずれも減少傾向を示したが、有意な効果は認められなかった。また、投与期間中に病理的な所見からの副作用は、全く見られなかった。なお、表中のp値はTukey-Kramer's testによる有意確率を示している。
前記実施例1で使用した試験試料1−1、試験試料2−1、及び試験試料3−1を試験試料として使用した。また、試料を含まない溶液を陰性試料とした。
6週齢、雄性ZDFラット(米国チャールスリバー社より購入)を、高脂肪食(リサーチダイエット社製)を用いて1ヶ月間予備飼育を行った後、体重を測定し、1群6匹に群分けした。各群のラットに、1日1回ゾンデを用いて試験試料1−1、試験試料2−1、及び試験試料3−1、並びに陰性試料の各溶液を体重400gにつき1mlずつ44日間連日経口投与した。投与開始から42日目のラットの体重を測定し、投与開始前の体重との差を増体量とした。また、投与開始の日から一週間に一度の割合で、一日の間に消費される餌の重さを測定し、この平均値を一日あたりの摂餌量とした。
ラット1匹1日あたりの摂餌量と42日間の増体量を表2に示す。試験試料1−1、試験試料2−1、及び試験試料3−1を投与した群は、いずれも陰性試料を投与した群に比して摂餌量の顕著な増減は認められなかった。また、増体量(体重の増加)に関しても陰性試料を投与した群とほぼ同等であった。従って、ロフェノール骨格を持つ化合物は、ラットの餌の摂取量及び体重増加に影響を与えないことが判明した。
Claims (4)
- 4−メチルコレスト−7−エン−3−オール、4−メチルエルゴスト−7−エン−3−オール、及び4−メチルスチグマスト−7−エン−3−オールからなる群から選ばれる化合物を有効成分として含有する内臓脂肪蓄積抑制剤。
- 前記化合物を少なくとも0.001質量%含有する請求項1に記載の内臓脂肪蓄積抑制剤。
- 4−メチルコレスト−7−エン−3−オール、4−メチルエルゴスト−7−エン−3−オール、及び4−メチルスチグマスト−7−エン−3−オールからなる群から選ばれる化合物を含むユリ科植物の酢酸エチル/ブタノール混合液抽出物、若しくはクロロホルム/メタノール混合液抽出物、又はこれらの分画物を含有する内臓脂肪蓄積抑制剤であって、前記ユリ科植物の酢酸エチル/ブタノール混合液抽出物、若しくはクロロホルム/メタノール混合液抽出物、又はこれらの分画物が該化合物を乾燥質量で少なくとも0.001質量%含有する組成物を有効成分として含有する内臓脂肪蓄積抑制剤。
- 4−メチルコレスト−7−エン−3−オール、4−メチルエルゴスト−7−エン−3−オール、及び4−メチルスチグマスト−7−エン−3−オールからなる群から選ばれる化合物、又は該化合物を乾燥質量で少なくとも0.001質量%含有するユリ科植物の酢酸エチル/ブタノール混合液抽出物、若しくはクロロホルム/メタノール混合液抽出物、又はこれらの分画物を有効成分として配合することを特徴とする、内臓脂肪蓄積抑制剤の製造方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005275172 | 2005-09-22 | ||
JP2005275172 | 2005-09-22 | ||
JP2005287888 | 2005-09-30 | ||
JP2005287888 | 2005-09-30 | ||
PCT/JP2006/318686 WO2007043294A1 (ja) | 2005-09-22 | 2006-09-21 | 内臓脂肪蓄積抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP4164538B2 true JP4164538B2 (ja) | 2008-10-15 |
JPWO2007043294A1 JPWO2007043294A1 (ja) | 2009-04-16 |
Family
ID=37942546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007539844A Active JP4164538B2 (ja) | 2005-09-22 | 2006-09-21 | 内臓脂肪蓄積抑制剤 |
Country Status (11)
Country | Link |
---|---|
US (2) | US8093233B2 (ja) |
EP (1) | EP1927360B1 (ja) |
JP (1) | JP4164538B2 (ja) |
KR (1) | KR100935813B1 (ja) |
CN (2) | CN101804144A (ja) |
AU (1) | AU2006300629B2 (ja) |
CA (1) | CA2611181C (ja) |
ES (1) | ES2449744T3 (ja) |
HK (1) | HK1119403A1 (ja) |
RU (1) | RU2419438C2 (ja) |
WO (1) | WO2007043294A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4162703B2 (ja) * | 2005-09-22 | 2008-10-08 | 森永乳業株式会社 | 内臓脂肪蓄積抑制剤 |
CN102216317B (zh) * | 2008-11-19 | 2015-07-22 | 森永乳业株式会社 | 抗氧化剂 |
US8486899B2 (en) * | 2008-11-19 | 2013-07-16 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
WO2016084957A1 (ja) * | 2014-11-28 | 2016-06-02 | 森永乳業株式会社 | マトリックスメタロプロテアーゼ産生阻害剤 |
EP3729972A4 (en) * | 2017-12-19 | 2021-08-25 | Morinaga Milk Industry Co., Ltd. | PROCESS FOR THE PRODUCTION OF AN ALOE POWDER |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851224A (en) * | 1986-06-05 | 1989-07-25 | Carrington Laboratories, Inc. | Process for preparation of aloe products |
US4841224A (en) * | 1987-11-10 | 1989-06-20 | Washington Technology Center | Gap width probe and method |
JP3029907B2 (ja) | 1991-12-20 | 2000-04-10 | 理化学研究所 | 抗肥満剤 |
FR2706454B1 (fr) * | 1993-06-17 | 1995-09-15 | Roussel Uclaf | Nouveaux 19-Nor stéroïdes, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant. |
JP3862295B2 (ja) | 1993-09-30 | 2006-12-27 | 独立行政法人理化学研究所 | 抗肥満剤 |
JP3966922B2 (ja) | 1996-07-18 | 2007-08-29 | 一丸ファルコス株式会社 | 線維芽細胞増殖促進剤 |
GB9704904D0 (en) * | 1997-03-10 | 1997-04-30 | Riley Fletcher Foundation The | Essential oil composition |
JP3873097B2 (ja) | 1997-11-06 | 2007-01-24 | 独立行政法人理化学研究所 | 抗肥満剤及び脂質代謝改善剤 |
NZ330439A (en) | 1998-05-15 | 2001-01-26 | Immuno Lab Ltd | Dietary supplements comprising collagen hydrosylate, aloe vera, hydroxy citric acid, L-carnitine and water for weight loss |
US6506387B1 (en) * | 1999-04-28 | 2003-01-14 | Paxa N.V. | Method for preparing aloin by extraction |
JP4499209B2 (ja) * | 1999-05-10 | 2010-07-07 | 日本メナード化粧品株式会社 | 肥満の予防改善剤 |
JP3858055B2 (ja) | 2000-02-29 | 2006-12-13 | 独立行政法人理化学研究所 | 抗肥満剤及び脂質代謝改善剤 |
IN188857B (ja) * | 2000-07-14 | 2002-11-16 | Govind Kane Dr Shantaram | |
FR2811984B1 (fr) * | 2000-07-19 | 2004-02-06 | Pharmascience Lab | Procede de preparation d'un ester de corps gras et son utilisation dans les domaines pharmaceutique, cosmetique ou alimentaire |
RU2192876C2 (ru) | 2001-01-30 | 2002-11-20 | Савина Лидия Васильевна | Способ снижения уровня липидов |
CN1426702A (zh) | 2001-12-21 | 2003-07-02 | 游绍裘 | 一种维持肠道健康、协助消减腹部肥胖的保健食品 |
JP2003286185A (ja) | 2002-03-29 | 2003-10-07 | Daily Foods Kk | アロエベラ圧搾液及び該圧搾液を有効成分とする血糖値降下剤 |
JP2007523849A (ja) * | 2003-05-31 | 2007-08-23 | フォーブス メディ−テック インコーポレーテッド | 1種以上のフィトステロール及び/又はフィトスタノール、及びグルコマンナンを含む組成物、及びii型糖尿病を有する又は有さない個体の脂質疾患の治療における該組成物の使用。 |
JP2005015425A (ja) | 2003-06-27 | 2005-01-20 | Kao Corp | 脂質代謝改善剤 |
EP1731158B1 (en) | 2004-03-31 | 2014-10-08 | Morinaga Milk Industry Co., Ltd. | Drug and food or drink for improving hyperglycemia |
-
2006
- 2006-09-21 CN CN201010164375A patent/CN101804144A/zh active Pending
- 2006-09-21 JP JP2007539844A patent/JP4164538B2/ja active Active
- 2006-09-21 KR KR1020077025775A patent/KR100935813B1/ko active IP Right Grant
- 2006-09-21 EP EP06798178.7A patent/EP1927360B1/en active Active
- 2006-09-21 RU RU2007146364/15A patent/RU2419438C2/ru not_active IP Right Cessation
- 2006-09-21 CA CA2611181A patent/CA2611181C/en active Active
- 2006-09-21 CN CN2006800236573A patent/CN101212976B/zh active Active
- 2006-09-21 US US11/913,758 patent/US8093233B2/en active Active
- 2006-09-21 ES ES06798178.7T patent/ES2449744T3/es active Active
- 2006-09-21 AU AU2006300629A patent/AU2006300629B2/en active Active
- 2006-09-21 WO PCT/JP2006/318686 patent/WO2007043294A1/ja active Application Filing
-
2008
- 2008-10-13 HK HK08111297.9A patent/HK1119403A1/xx not_active IP Right Cessation
-
2010
- 2010-07-21 US US12/841,076 patent/US8518924B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2006300629A1 (en) | 2007-04-19 |
EP1927360A1 (en) | 2008-06-04 |
US20100286104A1 (en) | 2010-11-11 |
RU2419438C2 (ru) | 2011-05-27 |
AU2006300629B2 (en) | 2009-12-10 |
CN101212976A (zh) | 2008-07-02 |
CA2611181C (en) | 2010-11-02 |
CN101804144A (zh) | 2010-08-18 |
KR20080011283A (ko) | 2008-02-01 |
WO2007043294A1 (ja) | 2007-04-19 |
WO2007043294A9 (ja) | 2007-06-14 |
HK1119403A1 (en) | 2009-03-06 |
CN101212976B (zh) | 2010-12-29 |
CA2611181A1 (en) | 2007-04-19 |
ES2449744T3 (es) | 2014-03-21 |
US8518924B2 (en) | 2013-08-27 |
US8093233B2 (en) | 2012-01-10 |
US20090093450A1 (en) | 2009-04-09 |
EP1927360B1 (en) | 2014-01-22 |
KR100935813B1 (ko) | 2010-01-08 |
EP1927360A4 (en) | 2010-09-29 |
RU2007146364A (ru) | 2009-06-20 |
JPWO2007043294A1 (ja) | 2009-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3905913B2 (ja) | 高血糖改善のための医薬及び飲食品 | |
KR100843508B1 (ko) | 고혈당 개선용 의약 | |
KR100967313B1 (ko) | 인슐린 저항성 개선제 | |
JP4164538B2 (ja) | 内臓脂肪蓄積抑制剤 | |
WO2006123466A1 (ja) | 膵臓機能改善のための医薬又は飲食品 | |
JP4162703B2 (ja) | 内臓脂肪蓄積抑制剤 | |
RU2315601C1 (ru) | Лекарственное средство и пищевой продукт или напиток для снижения гипергликемии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080722 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080728 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110801 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4164538 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110801 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120801 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120801 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130801 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |